Oncologist Founded-and-Funded Startup
Redefining cancer care with tumor responsive nanomedicines.
Our goal is to reinvigorate the treatment landscape for difficult-to-target tumors that are surrounded by dense stromal tissue. We mimic the self-assembly of DNA to create unprecedentedly small nanomedicines, each containing a duo of anti-cancer therapies, that can extravasate deep within tumors. Unique conditions within the tumor microenvironment cleave the environmentally sensitive bonds of our nanomedicines, releasing therapy directly in the tumor - exactly where it needs to be.
Company
At Duo Oncology, we have brought together practicing clinical oncologists and diverse pharmaceutical scientists to develop simple, elegant nanomedicines for patients with cancer. We streamline operations with a team of select, globally recognized experts who are efficiently guiding our nanomedicines through the complex drug approval process to quickly reach patients.
Platform
Duo’s nanomedicine platform features ultrasmall particles that deliver large drug payloads directly to the tumor, even tumor surrounded by obstructive stromal tissue. Our proprietary chemistry borrows from the self-assembly of DNA to pack diverse drugs into particles 10X smaller than competing products. We customize this optimized particle platform into powerful combination therapies for patients with stroma-rich tumors.
Pipeline
As a company, we’re developing a pipeline that addresses the greatest unmet needs in cancer treatment. Cancer patients respond best to regimens with multiple drugs, so each of our nanomedicines combine two powerful anti-cancer therapies into a single treatment. Our nanomedicines produce superior outcomes when compared to equivalent regimens lacking our proprietary particles. We develop each new candidate nanomedicine to meet known critical needs in orphan cancer indications and other hard to treat tumors prevalent around the globe.